The Past, Current and Future of Cross-Border ADC Dealmaking | 直播

【重磅录像】颜宁：“AI在结构生物学中的未达之地”

SAPA-GP Webinar

SAPA-GP Webinar welcome you to attend:

BioVerse: Where Science Sparks Business【Episode 003】

The Past, Current and Future of Cross-Border ADC Dealmaking | 直播

Introduction

The global pharmaceutical scene is ablaze with ADC developments, inspired by AstraZeneca/Daiichi’s $6.9B deal in 2020 and Merck/Daiichi’s ~$22B partnership in 2023. China’s biotech firms like Kelun, Duality, KYM, MediLink, and Hansoh have forged impressive global alliances, contributing to over 60% of new ADC projects recently. With substantial clinical data releases, China’s biotechs are fueling the cross-border ADC deal surge.

Join the Bioverse webinar to explore how long this trend will last, the key ADC success factors, and common strengths and weaknesses of China’s ADC assets. Insights from Merck, AstraZeneca, Duality, and MediLink await!

Speaker:

Nikhil Mutyal, Ph.D.

Executive Director

Business Development and Licensing

Merck and Co

Yang Qiu, Ph.D.

Chief Scientific Officer and US GM

Duality Biologics

Joey (Liang) Xiao, Ph.D.

COO and Co-founder

MediLink Therapeutics

Shunfei (Stephen) Yan, Ph.D.

Medical Evaluation Manager

AstraZeneca China

Moderator:

Leon ‘Jun’ Tang, Ph.D., M.S.

Founder of InScienceWeTrust

Community

Organizers:

Partners & Collaborators:

| /

★

Registration

Date and Time:

Wednesday, Nov 8, 8:00 PM to 9:00 PM (EST)

Thursday, Nov 9, 9:00 AM to 10:00 AM (BJT)

Speaker’s Bio

Nikhil MutyalExecutive Director Business Development and LicensingMerck and Co

上下滑动查看完整介绍

Dr. Nikhil Mutyal is Executive Director, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology, Neuroscience and Cardiometabolic diseases for therapeutic opportunities from companies and research initutes based in Western US/CAN, SE Asia, ANZ. Dr. Mutyal’s professional career spans across management consulting for pharma/biotech and BD roles across various companies. Dr. Mutyal received his Ph.D. in Biomedical Engineering (Cancer Research) from Northwestern University and has B.S. and M.S. in Medicinal Chemistry from Indian Institute of Technology, Kanpur.

Yang QiuChief Scientific Officerand US GM

Duality Biologics

上下滑动查看完整介绍

Dr. Qiu Yang has over 20 years of MNC drug discovery and development experience with demonstrated success of leading drug discovery, translational medicine and early clinical development programs. She contributed to the discovery and progression into clinic of over 15 drug candidates and drug approvals including the most recent FDA BTD Patritumab Deruxtecan (HER3-DXd).

Previously as Co-chair of cross-ADC program, Senior Director of Translational Medicine at Daiichi Sankyo; Director, Head of Translational and Biomarker Research at Janssen; Director, Head of Molecular Discovery Research at GSK China.

Postdoc in Human Genomics at Lawrence Berkeley National Lab, PhD in Molecular Biology from University of Texas at Austin, and college from University of Science and Technology in China.

Joey (Liang) XiaoCOO and Co-founderMediLink Therapeutics

上下滑动查看完整介绍

Dr. Liang Xiao is the COO and Co-founder of MediLink Therapeutics. Dr. Liang Xiao is primarily responsible for ADC drug preclinical development and external cooperation in business development at MediLink. With 16 years of experience in both academia and the biopharmaceutical industry, Dr. Xiao previously served as the VP of Biologics R&D at Kelun-Biotech, where he was responsible for the development of multiple innovative biologics from 2013 to 2020. These projects resulted in global licensing agreements with multinational companies, totaling over $12 billion in value.Dr. Xiao has successfully led 15 monoclonal antibody, bispecific antibody, and ADC projects into clinical stages. Among them, two monoclonal antibody projects and one ADC project have been submitted for BLA. Additionally, one ADC project is currently in Phase III clinical stage, and four ADC projects are in Phase I clinical stage.Dr. Xiao holds a Bachelor’s degree in Life Sciences from the University of Science and Technology of China, as well as a Ph.D. degree in Chemical Engineering from the University of Southern California.

Shunfei (Stephen) YanMedical Evaluation ManagerAstraZeneca China

上下滑动查看完整介绍

Shunfei is currently a medical evaluation manager at AZ China where he is responsible for searching & evaluating potential external partnership opportunities. Before joining AZ, Shunfei spent multiple years in venture capital domain where he served as an investment manager at Fosun Health Capital and Lingang Wonder-of-Land Capital with a focus on innovative medicines. Shunfei received his PhD degree in oncology from the University of Melbourne where he conducted his study in synthetic lethality. Before that, he obtained his Master and Bachelor degree in Biological Sciences from Fudan University.